Novo Nordisk's shares experienced a decline today
In a surprising turn of events, pharmaceutical giant Novo Nordisk has abruptly terminated its partnership with telehealth company Hims & Hers Health, Inc., effective from June 2025. The collaboration, which lasted just over a month, came to an end due to concerns that Hims & Hers was engaging in deceptive marketing and selling illegitimate, compounded knockoff versions of Novo Nordisk's weight loss drug, Wegovy.
The termination of the partnership had a significant negative impact on Hims & Hers' stock, causing it to plunge approximately 30% immediately following the announcement. The telehealth company has publicly defended itself, accusing Novo Nordisk of trying to control clinical standards and patient choice to protect its branded drug.
Novo Nordisk, however, maintains that the move was to protect the brand and patient safety. They have stated that they are fully meeting national demand for Wegovy following the FDA’s resolution of prior shortages. The company will continue to make authentic Wegovy available through select telehealth partners that uphold safe and legal practices.
The split between the two companies underscores growing tensions between pharmaceutical companies and telehealth platforms over marketing control and drug authenticity. The dispute may impact the sales of compounded, copycat versions of Wegovy, as Novo Nordisk emphasises its commitment to maintaining the integrity and sales of the branded drug.
The escalating fallout from the termination of the partnership is also affecting Novo Nordisk's shares, with the company's shares lower by 4% as of 11 a.m. ET today. The breakup of the partnership highlights the competition for Wegovy, such as Eli Lilly's Zepbound, in the growing market for weight loss drugs.
CEO of Hims & Hers, Andrew Dudum, has given an interview with Bloomberg, where he accused Novo Nordisk of pushing his company to guide patients towards Wegovy. Dudum's remarks, if intended to hurt the stock price, have arguably been successful today. However, he also stated that Novo Nordisk has been losing market share and is under financial strain to drive sales.
Despite the dispute, the market for weight loss drugs still appears to have enough growth for all competitors. Wegovy sales have shown significant growth, increasing by 85% in the first quarter on a reported basis. Novo Nordisk claims Hims & Hers failed to comply with an agreement to stop the mass sales of compounded, copycat versions of Wegovy, and the dispute involves allegations of illegal activities by Hims & Hers.
As the situation unfolds, both companies are responding to the public fallout, with Hims & Hers management led by CEO Andrew Dudum, and Novo Nordisk emphasising their commitment to patient safety and authentic drug distribution. The weight loss drug market remains competitive, with both companies vying for a share in the growing industry.
- The termination of the partnership between Novo Nordisk and Hims & Hers Health has caused a substantial dip in Hims & Hers' stock, with a drop of approximately 30% immediately following the announcement.
- Novo Nordisk claims Hims & Hers failed to comply with an agreement to stop the mass sales of compounded, copycat versions of Wegovy, and the dispute involves allegations of illegal activities by Hims & Hers.
- The disagreement between the two companies highlights the growing competition in the market for weight loss drugs, with other products like Eli Lilly's Zepbound representing potential rivals to Wegovy.
- Both companies are responding to the public fallout, with Hims & Hers management, led by CEO Andrew Dudum, defending the company's actions, and Novo Nordisk emphasizing their commitment to patient safety and authentic drug distribution.
